Scan beyond Personalis' widening losses to compare it with 36 healthcare AI stocks, which pairs revenue traction with different spending and profitability profiles.
To own Personalis, you need to be comfortable with a story in which minimal residual disease testing and broader precision oncology adoption eventually justify today’s heavy spending. The latest quarter keeps that tension front and center. Sales were US$25.6m with a net loss of US$33.8m, so higher activity is still coming with sizeable operating losses.
In the short term, the key swing factor remains how quickly reimbursement and mix shift can improve gross margins. The biggest risk is that cash burn and larger losses persist near current levels, which could keep pressure on funding needs. The third quarter figures do not ease that concern.
The analyst consensus Narrative on Simply Wall St points to accelerating NeXT Personal adoption, expanding Medicare coverage and MRD focused biopharma work as the levers that could improve Personalis’ economics over time. The third quarter update fits that storyline on revenue, yet the larger net loss underlines how dependent the thesis is on future margin progress rather than just volume.
With no new major corporate announcements around deals or reimbursement tied directly to this earnings release, the most relevant reference point remains the planned Tempus acquisition described in that same Narrative. Execution around that transaction, including any changes to timing or terms, sits alongside cash usage and reimbursement as core issues investors will likely watch after these results.
Personalis' narrative projects US$165.2m revenue and US$26.8m earnings by 2029. That outlook relies on analysts' assumption of 33.4% yearly revenue growth and an earnings swing of about US$134m from current earnings of a US$107.2m loss.
Uncover why Personalis' fair value indicates a 3% potential downside to its current price, which leaves little room for error.
One bearish twist you might want to explore focuses on margins at Personalis. The lowest analysts already expected revenue of about US$171.2m and earnings of roughly US$27.3m in 2029, yet still built a more cautious story around gross profit pressure. That more pessimistic view could shift again once these fresh quarterly losses are fully reflected in the numbers.
Explore another Personalis fair value estimate, including one that suggests it could be worth just $15.17.
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
If Personalis has you thinking harder about risk, returns and balance sheets, it can help to widen the search and compare it with other businesses screened on consistent fundamentals.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com